3M’s Road Ahead: Will the Stock Find Stability in Three Years?

3M (NYSE: MMM) is a name most investors recognize, a former Dividend King that was once synonymous with stability and steady growth. Yet, the last few years have been a tough pill to swallow for the industrial giant. A combination of slowing growth, legal challenges, and significant structural changes has left shareholders wondering: what’s next? Let’s break it down.

3M’s Recent Struggles: What Went Wrong?

The company has seen better days. Between 2021 and 2023, organic sales growth took a nosedive, and operating margins suffered a similar fate. What happened? Inflation, rising interest rates, and geopolitical instability all played their parts. But there’s more to the story.

3M’s extensive product lineup—over 60,000 items, including household names like Scotch Tape and Post-it Notes—failed to provide the stability investors once relied upon. The healthcare division, now spun off as Solventum, was the lone bright spot, but even that couldn’t offset weaknesses in other segments.

And then there’s the legal mess. The company has faced waves of lawsuits over PFAS, so-called “forever chemicals,” and defective earplugs. These lawsuits have already cost billions, with more to come. At the end of its most recent quarter, 3M reported negative operating cash flow of $1.8 billion and a debt load that far outweighs its cash reserves.

One thing is clear: 3M isn’t the dependable company it once was.

What Can Investors Expect Under New Leadership?

In May 2024, Bill Brown took over as CEO, bringing a fresh perspective and a mandate to stabilize 3M’s floundering operations. His plan? It’s ambitious, focusing on a few key areas:

• Rebalancing the portfolio: Brown intends to pivot older products toward growth markets.
• Exploring M&A: While specifics are thin, mergers and acquisitions could play a role in 3M’s recovery.
• Streamlining R&D: The company aims to make its research efforts more focused and cost-effective.
• Improving supply chains: After several costly quality control mishaps, this is a high priority.

These steps could help 3M regain some footing, but progress is likely to be slow. For 2024, the company expects organic sales growth of just 1% and a steep drop in adjusted earnings per share. This doesn’t exactly scream “turnaround success.”

Is 3M’s Stock Cheap or Just Risky?

At around $134.60 per share, 3M trades at 17 times its forward earnings—a significant discount compared to historical levels. However, this valuation reflects the many risks tied to the stock.

Some key considerations:

• Dividend appeal is fading: After cutting its payout in 2024, the dividend yield now sits at 2.1%. That’s less enticing in today’s high-interest-rate environment.
• Ongoing legal risks: The company still faces billions in potential liabilities from PFAS-related lawsuits and product recalls.
• Unclear growth trajectory: Even with a strategic overhaul, the timeline for visible results remains uncertain.

In short, while the valuation might look attractive on the surface, it’s hard to ignore the challenges ahead.

How Does 3M Stack Up Against Its Peers?

To put things into perspective, here’s a quick look at how 3M compares to some of its competitors in the industrial sector:

*Estimated for 2024

Honeywell and Illinois Tool Works offer better growth prospects and slightly higher dividend yields, making them more attractive options for many investors.

The Bottom Line: Proceed with Caution

For investors considering 3M, the key question is whether the company can overcome its current hurdles. While it’s not a lost cause, the path forward is murky. Legal challenges, slow growth, and a weakened dividend make it difficult to justify a significant investment at this point.

That said, the stock might appeal to long-term investors with a high tolerance for risk. If 3M’s turnaround efforts start to gain traction, there’s room for upside. But until there’s more clarity, many will likely find better opportunities elsewhere.